Journal of Nephrology

SIN
Italian Society of Nephrology
www.sin-italy.org

Journal of Nephrology

GENERAL INFORMATION

The ***Journal of Nephrology*** (J Nephrol) considers the publication of peer reviewed original manuscripts dealing with both clinical and laboratory investigations of relevance to the broad fields of Nephrology, Dialysis and Transplantation. Submission of research manuscripts covering diverse topics and problems (**Original Articles**) is encouraged. However, comprehensive reviews on relevant topics (**Reviews** - *Thorough Critical Appraisal*), reports of clinical cases of special interest (**Case Reports**), and brief reports on the protocols of new ongoing trials (**Research Protocols**) will also be considered. Finally, the Journal will publish also articles (by invitation) in the following features: **Methods and Science in Nephrology**, **Public Health and Preventive Nephrology**, **Scanned from the Bench**, **News and Nephrology**, **JN Sounding Board** (*Commentaries*). Although the Editors and referees make every effort to ensure the validity of published manuscripts, the final responsibility rests with the Authors, not with the Journal, its Editors, the Italian Society of Nephrology or the Publisher.

SUBSCRIPTION 2011
Six issues: INDIVIDUAL: Europe € 249; Other countries € 290. INSTITUTION*: Europe € 369; Other countries € 410. RESIDENTS: Europe € 187; Other countries € 228. ONLINE ONLY: Individual € 191; Institution € 290; Residents € 110.
Single copy: € 65.
Back issue: € 70.
* Libraries, universities, hospitals, public health services, manufacturers

Orders can be placed with any bookstore or directly with Wichtig Editore, Via Friuli 72, 20135 Milano - Italy
Phone: +39 02 5455122 - 02 55195443
Fax: +39 02 55195971 - *subscriptions@wichtig.it*

SUBSCRIPTION FOR USA AND CANADA
Subscriptions for USA and Canada should be sent to our address:
Journal of Nephrology
EBSCO - P.O. BOX 830350
Birmingham, Alabama 35283-0350 USA
Phone: 1-800-633-4931 - Fax: 1-205-995-1588

This journal is indexed in:
INDEX MEDICUS / MEDLINE
CURRENT CONTENTS® / CLINICAL MEDICINE
SCISEARCH®
RESEARCH ALERT®
EMBASE / Excerpta Medica
BIOSIS
IndexCopernicus

Published bimonthly by
Wichtig Editore
Via Friuli, 72
20135 Milano - Italy
Tel. 0039 02 55195443 or 02 5455122
Fax 0039 02 55195971
www.wichtig-publisher.com

PUBLISHING MANAGER: Diego Brancaccio
diego.brancaccio@tiscali.it

PRODUCTION EDITOR
Marta Costantino
marta.costantino@wichtig.it

SUBSCRIPTION and CIRCULATION
Marina Tresoldi
marina.tresoldi@wichtig.it

ADVERTISING and PROMOTION
Nella Bini
nella.bini@wichtig.it

PRINTED BY
Print Management Group srl
San Giuliano Milanese, Milano - Italy

ISSN 1121-8428
E-ISSN 1724-6059
Reg. Tribunale di Milano n. 488 del 7-8-1992
DIRETTORE RESPONSABILE: Diego Brancaccio



Vol. 24 • No. 1
January-February 2011

www.sin-italy.org
www.jnephrol.com

CONTENTS

THOROUGH CRITICAL APPRAISALS

REVIEW

ORIGINAL ARTICLES



ORIGINAL ARTICLES

CASE REPORTS

ORIGINAL ARTICLE

JNEPHROL 2011; 24(01): 106-111

DOI:10.5301/JN.2010.5094

Effect of IL-11 on glomerular expression of TGF-beta and extracellular matrix in nephrotoxic nephritis in Wistar Kyoto rats

Maria Stangou [1], Gurjeet Bhangal [1], Ping-Chin Lai [1,2], Jennifer Smith [1], James C. Keith Jr [3], Joseph J. Boyle [4], Charles D. Pusey [1], Terence Cook [1,4], Frederick W.K. Tam [1]

[1] Imperial College Kidney and Transplant Institute, Division of Medicine, Imperial College London, London - UK
[2] Kidney Institute, Department of Nephrology, Chang Gung Memorial Hospital, School of Medicine, Chang Gung University, Taoyuan - Taiwan
[3] Wyeth Research, Cambridge, Massachusetts - USA
[4] Department of Histopathology, Hammersmith Hospital, London - UK

ABSTRACT

Background: **The effect of interleukin-11 (IL-11) on transforming growth factor-β (TGF-β) is controversial and has not been examined in renal diseases. In this study, we (i) characterised the up-regulation of TGF-β1, phospho-p38 MAPK (p-p38 MAPK) and extracellular matrix during pathogenesis of glomerulonephritis and (ii) examined the effect of rhIL-11 on these processes in vivo.**

Methods: **Following induction of nephrotoxic nephritis, expression of TGF-β1, α-smooth muscle actin (α-SMA), fibronectin and p-p38 MAPK was detected in the kidney. Rats were treated either with vehicle or rhIL-11 at a high or low dose and culled on day 6.**

Results: **A high dose of rhIL-11 resulted in a significant reduction in the glomerular expression of TGF-β1 (0.4 ± 0.1 vs. 2.04 ± 0.4 semiquantitative score, $p<0.005$), α-SMA (0.6 ± 0.2 vs. 1.5 ± 0.3, $p<0.01$) and fibronectin (0.6 ± 0.1 vs. 1.5 ± 0.1, $p<0.02$). The periglomerular expression of α-SMA and fibronectin was significantly reduced in rats treated with the high dose of rhIL-11 (9.6% ± 2% vs. 92% ± 2.5% of glomeruli, $p<0.01$; and 26% ± 4.9% vs. 94% ± 1.9% of glomeruli, $p<0.005$, respectively). There was a slight but insignificant reduction of p-p38 MAPK in IL-11 treated rats. Treatment with low-dose rhIL-11 did not reduce expression of these molecules.**

Conclusion: **IL-11 suppresses glomerular expression of TGF-β1 and extracellular matrix deposition in experimental glomerulonephritis.**

Key words: *Extracellular matrix, Glomerulonephritis, IL-*

INTRODUCTION

Interleukin-11 (IL-11) is a pleiotropic cytokine which exerts different actions in various cell types (1-3). Recombinant human IL-11 (rhIL-11) is clinically indicated in the treatment of chemotherapy-induced thrombocytopenia (4, 5) and in von Willebrand disease (6). The effect of IL-11 on fibrosis is controversial. It inhibits fibroblast proliferation in vitro (7) and ameliorates fibrosis in the HLA-B27 rat model of inflammatory bowel disease (8), but its overexpression in transgenic mice leads to lung fibrosis and airway obstruction (9). In previous studies, we have demonstrated that treatment with rhIL-11 reduces acute inflammation in nephrotoxic nephritis (NTN) in rats and mice (10, 11). NTN resembles human necrotizing and crescentic glomerulonephritis. Its pathogenesis and natural history have been characterised previously (12).

In this study, we report the effect of IL-11 on the expression of transforming growth factor-β1 (TGF-β1), a key profibrotic growth factor; α-smooth muscle actin (α-SMA), a myofibroblast marker; fibronectin, a component of extracellular matrix; and phospho-p38 MAPK (p-p38MAPK), a signal transduction pathway, in NTN in rats. TGF-β, as a positive regulator of myofibroblast differentiation, has a central role in the development and progression of fibrosis. The MAPK signalling pathway has been shown to exhibit cross-talk with the TGF-β signalling pathway; TGF-β-induced α-SMA expression and myofibroblast differentiation require the activation of MAPKs (13, 14).

To our knowledge, this is the first evidence that IL-11 treatment may retard glomerular expression of TGF-β1 and ex-

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.